Arritmias en Enfermedad Renal Cronica, Mecanismos Implicados, Repercusion y Terapeutica de esta Compleja Asociacion
Palabras clave:
arritmia, enfermedad renal crónica, muerte súbita cardiaca, diálisis, fibrilación auricular
Resumen
Las arritmias causan discapacidad y un mayor riesgo de muerte prematura en la población general, pero mucho más en pacientes con insuficiencia renal. La asociación entre los sistemas cardíaco y renal es compleja y se deriva en parte de la causalidad común de lesión renal y miocárdica por afecciones que incluyen hipertensión y diabetes. En muchos casos, existe una relación causal, con disfunción renal que promueve arritmias y arritmias que exacerban la disfunción renal. En esta revisión, los autores amplían los desafíos que enfrentan los cardiólogos en el tratamiento de arritmias comunes y poco comunes en pacientes con insuficiencia renal mediante intervenciones farmacológicas, ablación y terapias con dispositivos cardíacos implantables.
Descargas
La descarga de datos todavía no está disponible.
Citas
1. Krijthe BP, Kunst A, Benjamin EJ et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34:2746–51. doi: 10.1093/eurheartj/eht280.
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–858. doi: 10.1016/S0140-6736(18)32279-7.
3. Chiu DYY, Sinha S, Kalra PA, Green D. Sudden cardiac death in haemodialysis patients: preventative options. Nephrol (Carlton) 2014;19:740–9. doi: 10.1111/nep.12337.
4. Kim ED, Soliman EZ, Coresh J et al. Two-week burden of arrhythmias across ERC severity in a large community-based cohort: the ARIC study. J Am Soc Nephrol. 2021;32:629–38. doi: 10.1681/ASN.2020030301.
5. Rautavaara J, Kerola T, Kaartinen K et al. Asystole episodes and bradycardia in patients with end-stage renal disease. Nephrol Dial Transplant. 2022;37:575–83. doi: 10.1093/ndt/gfab023.
6. Pisani A, Visciano B, Imbriaco M et al. The kidney in Fabry's disease. Clin Genet. 2014;86:301–9. doi: 10.1111/cge.12386.
7. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol. 2002;13((Suppl 2)):S134–8. doi: 10.1097/01.ASN.0000016684.07368.75.
8. Jaurretche S, Antogiovanni N, Perretta F. Prevalence of chronic kidney disease in fabry disease patients: multicenter cross sectional study in Argentina. Mol Genet Metab Rep. 2017;12:41–3. doi: 10.1016/j.ymgmr.2017.05.007.
9. Shah JS, Hughes DA, Sachdev B et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol. 2005;96:842–6. doi: 10.1016/j.amjcard.2005.05.033.
10. Acharya D, Robertson P, Neal Kay G et al. Arrhythmias in Fabry cardiomyopathy. Clin Cardiol. 2012;35:738–40. doi: 10.1002/clc.22047.
11. Gulati A, Jabbour A, Ismail TF et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309:896–908. doi: 10.1001/jama.2013.1363.
12. Turakhia MP, Blankestijn PJ, Carrero JJ et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J. 2018;39:2314–25. doi: 10.1093/eurheartj/ehy060.
13. Baig S, Edward NC, Kotecha D et al. Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. Europace. 2018;20:f153–61. doi: 10.1093/europace/eux261.
14. Tang W, McDonald SP, Hawley CM et al. End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases. Nephrol Dial Transplant. 2013;28:455–61. doi: 10.1093/ndt/gfs492.
15. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006;166:1805–13. doi: 10.1001/archinte.166.17.1805.
16. Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac amyloidosis. JACC Clin Electrophysiol. 2020;6:351–61. doi: 10.1016/j.jacep.2020.01.004.
17. Barbhaiya CR, Kumar S, Baldinger SH et al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm. 2016;13:383–90. doi: 10.1016/j.hrthm.2015.09.016.
18. Staron A, Zheng L, Doros G et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021;11:139. doi: 10.1038/s41408-021-00529-w.
19. Staude H, Jeske S, Schmitz K et al. Cardiovascular risk and mineral bone disorder in patients with chronic kidney disease. Kidney Blood Press Res. 2013;37:68–83. doi: 10.1159/000343402.
20. Mirza MAI, Larsson A, Melhus H et al. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009;207:546–51. doi: 10.1016/j.atherosclerosis.2009.05.013.
21. Laukkanen JA, Khan H, Kurl S et al. Left ventricular mass and the risk of sudden cardiac death: a population-based study. J Am Heart Assoc. 2014;3:e001285. doi: 10.1161/JAHA.114.001285.
22. Inaba M, Okuno S, Imanishi Y et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int. 2006;17:1506–13. doi: 10.1007/s00198-006-0154-6.
23. Srivaths PR, Goldstein SL, Silverstein DM et al. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol. 2011;26:945–51. doi: 10.1007/s00467-011-1822-0.
24. Park CW, Oh YS, Shin YS et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis. 1999;33:73–81. doi: 10.1016/S0272-6386(99)70260-X.
25. Thorp ML, Johnson ES, Yang X et al. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology. 2009;14:240–6. doi: 10.1111/j.1440-1797.2008.01065.x.
26. Martinez-Vea A, Marcas L, Bardají A et al. Role of oxidative stress in cardiovascular effects of anemia treatment with erythropoietin in predialysis patients with chronic kidney disease. Clin Nephrol. 2012;77:171–81. doi: 10.5414/CN107309.
27. Drüeke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84. doi: 10.1056/NEJMoa062276.
28. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98. doi: 10.1056/NEJMoa065485.
29. Schüttler D, Schönermarck U, Wenner F et al. Large potassium shifts during dialysis enhance cardiac repolarization instability. J Nephrol. 2021;34:1301–5. doi: 10.1007/s40620-020-00880-4.
30. Weiss JN, Qu Z, Shivkumar K. Electrophysiology of hypokalemia and hyperkalemia. Circ Arrhythm Electrophysiol. 2017;10:e004667. doi: 10.1161/CIRCEP.116.004667.
31. Farkas JD, Long B, Koyfman A, Menson K. BRASH syndrome: bradycardia, renal failure, AV blockade, shock, and hyperkalemia. J Emerg Med. 2020;59:216–23. doi: 10.1016/j.jemermed.2020.05.001.
32. Orlov S, Cherney DZI, Pop-Busui R et al. Cardiac autonomic neuropathy and early progressive renal decline in patients with nonmacroalbuminuric type 1 diabetes. Clin J Am Soc Nephrol. 2015;10:1136–44. doi: 10.2215/CJN.11441114.
33. Schlaich MP, Socratous F, Hennebry S et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20:933–9. doi: 10.1681/ASN.2008040402.
34. Esler M. The autonomic nervous system and cardiac arrhythmias. Clin Auton Res. 1992;2:133–5. doi: 10.1007/BF01819669.
35. Baber U, Howard VJ, Halperin JL et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Circ Arrhythm Electrophysiol. 2011;4:26–32. doi: 10.1161/CIRCEP.110.957100.
36. Yu L, Huang B, Wang Z et al. Impacts of renal sympathetic activation on atrial fibrillation: the potential role of the autonomic cross talk between kidney and heart. J Am Heart Assoc. 2017;6:e004716. doi: 10.1161/JAHA.116.004716.
37. Pokushalov E, Romanov A, Corbucci G et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60:1163–70. doi: 10.1016/j.jacc.2012.05.036.
38. Yao C, Veleva T, Scott L et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. Circulation. 2018;138:2227–42. doi: 10.1161/CIRCULATIONAHA.118.035202.
39. Xintarakou A, Tzeis S, Psarras S et al. Atrial fibrosis as a dominant factor for the development of atrial fibrillation: facts and gaps. Europace. 2020;22:342–51. doi: 10.1093/europace/euaa009.
40. Vilaysane A, Chun J, Seamone ME The NLRP3 inflammasome promotes renal inflammation and contributes to ERC. J Am Soc Nephrol JASN. 2010. pp. 211732–44.
41. Chin LH, Hsu YJ, Hsu SC et al. The regulation of NLRP3 inflammasome expression during the development of cardiac contractile dysfunction in chronic kidney disease. Oncotarget. 2017;8:113303–17. doi: 10.18632/oncotarget.22964.
42. Yeyati NL, Adrogué HJ. Inappropriately high plasma renin activity accompanies chronic loss of renal function. Am J Nephrol. 1996;16:471–7. doi: 10.1159/000169046.
43. Ruiz-Ortega M, Lorenzo O, Suzuki Y et al. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens. 2001;10:321–9. doi: 10.1097/00041552-200105000-00005. (PubMed) (CrossRef) (Google Scholar)
44. Xiao HD, Fuchs S, Campbell DJ et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol. 2004;165:1019–32. doi: 10.1016/S0002-9440(10)63363-9. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Chen Shih , J. (2025). Relación entre inteligencia emocional y rendimiento académico en estudiantes de nivel superior de Arequipa en la postpandemia . Ciencia Y Reflexión, 4(2), 648–667. https://doi.org/10.70747/cr.v4i2.299
Alcántara , R. L. (2025). Acompañamiento Pedagógico Estrategia Colaborativa. Ciencia Latina Revista Científica Multidisciplinar, 9(3), 7881-7886. https://doi.org/10.37811/cl_rcm.v9i3.18412
Agila Mocha, R. J., Vivanco Ureña, C. I., León Bravo, F. E., & Reyes Carrión , J. P. (2025). Software Educativos para el Proceso de Enseñanza Aprendizaje de Matemáticas en Bachillerato. Ciencia Y Reflexión, 4(2), 1341–1369. https://doi.org/10.70747/cr.v4i2.334
Chen Shih , J. (2025). Relación entre inteligencia emocional y rendimiento académico en estudiantes de nivel superior de Arequipa en la postpandemia . Ciencia Y Reflexión, 4(2), 648–667. https://doi.org/10.70747/cr.v4i2.299
Quelal Morejón , C. E., Rogel Calderón , A. S., Loaiza Dávila , L. E., & Maqueira Caraballo, G. D. L. C. (2025). Los juegos predeportivos: una alternativa para la inclusión de estudiantes con Trastorno del Espectro Autista (TEA) a la clase de Educación Física. Arandu UTIC, 12(2), 2169–2189. https://doi.org/10.69639/arandu.v12i2.1055
Guadalupe Beltrán , E. S., Palomeque Zambrano, J. Y., & Loor Avila, B. A. (2025). Desafíos de la Educación Superior en Contextos Híbridos: Análisis de las Prácticas Docentes en la Universidad Estatal de Milagro durante el Periodo Académico 2025. Revista Veritas De Difusão Científica, 6(2), 1259–1281. https://doi.org/10.61616/rvdc.v6i2.685
Lozano Flores, L. D. (2025). Gamificación en el aprendizaje de unidades de tiempo: el caso de Sims 4. Emergentes - Revista Científica, 5(2), 68–86. https://doi.org/10.60112/erc.v5.i1.373
Velásquez Torres, A. O., González Bautista, G., Neira Vera , M., & García Montañez , A. M. (2025). Formación Docente en la Resolución Pacífica de Conflictos: Diagnóstico de una Necesidad Curricular en Colombia. Estudios Y Perspectivas Revista Científica Y Académica , 5(2), 2936–2952. https://doi.org/10.61384/r.c.a.v5i2.1329
Duarte Gahona, Y. K. (2025). Aplicación de la Inteligencia Artificial en la Personalización del Aprendizaje para Estudiantes con Necesidades Educativas Especiales . Revista Científica De Salud Y Desarrollo Humano , 6(2), 33–53. https://doi.org/10.61368/r.s.d.h.v6i2.575
45. Cao W, Song S, Fang G et al. Cadherin-11 deficiency attenuates Ang-II-induced atrial fibrosis and susceptibility to atrial fibrillation. J Inflamm Res. 2021;14:2897–911. doi: 10.2147/JIR.S306073.
46. Ishizaka N, Nakao A, Ohishi N et al. Increased leukotriene A(4) hydrolase expression in the heart of angiotensin II-induced hypertensive rat. FEBS Lett. 1999;463:155–9. doi: 10.1016/S0014-5793(99)01607-5.
47. Pueyo ME, Gonzalez W, Nicoletti A et al. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol. 2000;20:645–51. doi: 10.1161/01.ATV.20.3.645.
48. Goette A, Staack T, Röcken C et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. 2000;35:1669–77. doi: 10.1016/S0735-1097(00)00611-2.
49. Li Y, Li W, Yang B et al. Effects of cilazapril on atrial electrical, structural and functional remodeling in atrial fibrillation dogs. J Electrocardiol. 2007;40:100–e1–6. doi: 10.1016/j.jelectrocard.2006.04.001.
50. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res. 2002;54:456–61. doi: 10.1016/S0008-6363(02)00243-2.
51. Boldt A, Scholl A, Garbade J et al. ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol. 2006;101:261–7. doi: 10.1007/s00395-005-0571-2.
52. Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832–9. doi: 10.1016/j.jacc.2004.11.070.
53. Tanaka T, Nomura Y, Hirama C et al. Cardiac arrest during hemodialysis: a survey of five Japanese hospitals. Acute Med Surg. 2020;7:e476. doi: 10.1002/ams2.476.
54. Karnik JA, Young BS, Lew NL et al. Cardiac arrest and sudden death in dialysis units. Kidney Int. 2001;60:350–7. doi: 10.1046/j.1523-1755.2001.00806.x.
55. Douvris A, Malhi G, Hiremath S et al. Interventions to prevent hemodynamic instability during renal replacement therapy in critically ill patients: a systematic review. Crit Care. 2018;22:41. doi: 10.1186/s13054-018-1965-5.
56. Park S, Lee S, Kim Y et al. Atrial fibrillation and kidney function: a bidirectional Mendelian randomization study. Eur Heart J. 2021;42:2816–23. doi: 10.1093/eurheartj/ehab291.
57. El Hage N, Jaar BG, Cheng A et al. Frequency of arrhythmia symptoms and acceptability of implantable cardiac monitors in hemodialysis patients. BMC Nephrol. 2017;1:309. doi: 10.1186/s12882-017-0740-1.
58. Dalrymple LS, Go AS. Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:1487–93. doi: 10.2215/CJN.01290308.
59. James MT. Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. Arch Intern Med. 2008;168:2333. doi: 10.1001/archinte.168.21.2333.
60. Allon M, Depner TA, Radeva M et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO study. J Am Soc Nephrol. 2003;14:1863–70. doi: 10.1097/01.ASN.0000074237.78764.D1.
61. Bloom H, Heeke B, Leon A et al. Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery. Pacing Clin Electrophysiol. 2006;29:142–5. doi: 10.1111/j.1540-8159.2006.00307.x.
62. Baman TS, Gupta SK, Valle JA, Yamada E. Risk factors for mortality in patients with cardiac device-related infection. Circ Arrhythm Electrophysiol. 2009;2:129–34. doi: 10.1161/CIRCEP.108.816868.
63. Moss AJ, Hall WJ, Cannom DS et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–40. doi: 10.1056/NEJM199612263352601.
64. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83. doi: 10.1056/Nejmoa013474.
65. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37. doi: 10.1056/NEJMoa043399.
66. Turakhia MP, Varosy PD, Lee K et al. Impact of renal function on survival in patients with implantable cardioverter-defibrillators. Pacing Clin Electrophysiol. 2000;30:377–84. doi: 10.1111/j.1540-8159.2007.00678.x.
67. Sakhuja R, Keebler M, Lai T-S et al. Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator. Am J Cardiol. 2009;103:735–41. doi: 10.1016/j.amjcard.2008.11.014.
68. Korantzopoulos P, Liu T, Li L et al. Implantable cardioverter defibrillator therapy in chronic kidney disease: a meta-analysis. Europace. 2009;11:1469–75. doi: 10.1093/europace/eup282.
69. Makki N, Swaminathan PD, Hanmer J, Olshansky B. Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies. Europace. 2014;16:55–62. doi: 10.1093/europace/eut277.
70. Jukema JW, Timal RJ, Rotmans JI et al. Prophylactic use of implantable cardioverter-defibrillators in the prevention of sudden cardiac death in dialysis patients. Circulation. 2019;139:2628–38. doi: 10.1161/CIRCULATIONAHA.119.039818.
71. Okawa K, Miyoshi T, Sogo M et al. Improvement in renal and endothelial function after catheter ablation in patients with persistent atrial fibrillation. J Cardiol. 2020;76:610–7. doi: 10.1016/j.jjcc.2020.07.002.
72. Takahashi Y, Takahashi A, Kuwahara T et al. Renal function after catheter ablation of atrial fibrillation. Circulation. 2011;124:2380–7. doi: 10.1161/CIRCULATIONAHA.111.047266.
73. Naruse Y, Tada H, Sekiguchi Y et al. Concomitant chronic kidney disease increases the recurrence of atrial fibrillation after catheter ablation of atrial fibrillation: a mid-term follow-up. Heart Rhythm. 2011;8:335–41. doi: 10.1016/j.hrthm.2010.10.047.
74. Lee W, Wu P, Fang C et al. Impact of chronic kidney disease on atrial fibrillation recurrence following radiofrequency and cryoballoon ablation: a meta-analysis. Int J Clin Pract. 2021;75:e14173. doi: 10.1111/ijcp.14173.
75. Haïssaguerre M, Jaïs P, Shah DC et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659–66. doi: 10.1056/NEJM199809033391003.
76. Gallagher MM, Yi G, Gonna H et al. Multi-catheter cryotherapy compared with radiofrequency ablation in long-standing persistent atrial fibrillation: a randomized clinical trial. Europace. 2021;23:370–9. doi: 10.1093/europace/euaa289.
77. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406–12. doi: 10.1056/NEJM198908103210629.
78. Valembois L, Audureau E, Takeda A et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019;9:CD005049. doi: 10.1002/14651858.CD005049.pub5.
79. Waldo AL, Camm AJ, deRuyter H et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996;348:7–12. doi: 10.1016/S0140-6736(96)02149-6.
80. Tompkins C, Mclean R, Cheng A et al. End-stage renal disease predicts complications in pacemaker and ICD implants. J Cardiovasc Electrophysiol. 2011;22:1099–104. doi: 10.1111/j.1540-8167.2011.02066.x.
81. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. doi: 10.1056/NEJMoa0905561.
82. Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. doi: 10.1056/NEJMoa1107039.
83. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104. doi: 10.1056/NEJMoa1310907.
84. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. doi: 10.1056/NEJMoa1009638.
85. Medicines and Healthcare products Regulatory Agency. Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents. Drug Safety Update. 2020;13:5–7. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/896274/June-2020-DSU-PDF.pdf
86. Parker K, Thachil J. The use of direct oral anticoagulants in chronic kidney disease. Br J Haematol. 2018;183:170–84. doi: 10.1111/bjh.15564.
87. Elis A, Klempfner R, Gurevitz C et al. Apixaban in patients with atrial fibrillation and severe renal dysfunction: findings from a national registry. Isr Med Assoc J. 2021;23:353–8.
88. De Vriese AS, Caluwé R, Van Der Meersch H et al. Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol. 2021;32:1474–83. doi: 10.1681/ASN.2020111566.
89. Kimachi M, Furukawa TA, Kimachi K et al. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev. 2017;11:CD011373. doi: 10.1002/14651858.CD011373.pub2.
90. Genovesi S, Porcu L, Slaviero G et al. Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis. J Nephrol. 2021;34:63–73. doi: 10.1007/s40620-020-00774-5.
91. Mansour M, Karst E, Heist EK et al. The impact of first procedure success rate on the economics of atrial fibrillation ablation. JACC Clin Electrophysiol. 2017;3:129–38. doi: 10.1016/j.jacep.2016.06.002.
92. Brüggenjürgen B, Kohler S, Ezzat N et al. Cost effectiveness of antiarrhythmic medications in patients suffering from atrial fibrillation. Pharmacoeconomics. 2013;31:195–213. doi: 10.1007/s40273-013-0028-7. (PubMed) (CrossRef) (Google Scholar)
93. Neovius M, Jacobson SH, Eriksson JK et al. Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study. BMJ Open. 2014;4:e004251. doi: 10.1136/bmjopen-2013-004251.
94. Akhtar Z, Leung LWM, Sohal M, Gallagher MM. Leadless cardiac resynchronization therapy: a distant Utopia. Europace. 2021;23:81. doi: 10.1093/euro
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–858. doi: 10.1016/S0140-6736(18)32279-7.
3. Chiu DYY, Sinha S, Kalra PA, Green D. Sudden cardiac death in haemodialysis patients: preventative options. Nephrol (Carlton) 2014;19:740–9. doi: 10.1111/nep.12337.
4. Kim ED, Soliman EZ, Coresh J et al. Two-week burden of arrhythmias across ERC severity in a large community-based cohort: the ARIC study. J Am Soc Nephrol. 2021;32:629–38. doi: 10.1681/ASN.2020030301.
5. Rautavaara J, Kerola T, Kaartinen K et al. Asystole episodes and bradycardia in patients with end-stage renal disease. Nephrol Dial Transplant. 2022;37:575–83. doi: 10.1093/ndt/gfab023.
6. Pisani A, Visciano B, Imbriaco M et al. The kidney in Fabry's disease. Clin Genet. 2014;86:301–9. doi: 10.1111/cge.12386.
7. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol. 2002;13((Suppl 2)):S134–8. doi: 10.1097/01.ASN.0000016684.07368.75.
8. Jaurretche S, Antogiovanni N, Perretta F. Prevalence of chronic kidney disease in fabry disease patients: multicenter cross sectional study in Argentina. Mol Genet Metab Rep. 2017;12:41–3. doi: 10.1016/j.ymgmr.2017.05.007.
9. Shah JS, Hughes DA, Sachdev B et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol. 2005;96:842–6. doi: 10.1016/j.amjcard.2005.05.033.
10. Acharya D, Robertson P, Neal Kay G et al. Arrhythmias in Fabry cardiomyopathy. Clin Cardiol. 2012;35:738–40. doi: 10.1002/clc.22047.
11. Gulati A, Jabbour A, Ismail TF et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309:896–908. doi: 10.1001/jama.2013.1363.
12. Turakhia MP, Blankestijn PJ, Carrero JJ et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J. 2018;39:2314–25. doi: 10.1093/eurheartj/ehy060.
13. Baig S, Edward NC, Kotecha D et al. Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. Europace. 2018;20:f153–61. doi: 10.1093/europace/eux261.
14. Tang W, McDonald SP, Hawley CM et al. End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases. Nephrol Dial Transplant. 2013;28:455–61. doi: 10.1093/ndt/gfs492.
15. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006;166:1805–13. doi: 10.1001/archinte.166.17.1805.
16. Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac amyloidosis. JACC Clin Electrophysiol. 2020;6:351–61. doi: 10.1016/j.jacep.2020.01.004.
17. Barbhaiya CR, Kumar S, Baldinger SH et al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm. 2016;13:383–90. doi: 10.1016/j.hrthm.2015.09.016.
18. Staron A, Zheng L, Doros G et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021;11:139. doi: 10.1038/s41408-021-00529-w.
19. Staude H, Jeske S, Schmitz K et al. Cardiovascular risk and mineral bone disorder in patients with chronic kidney disease. Kidney Blood Press Res. 2013;37:68–83. doi: 10.1159/000343402.
20. Mirza MAI, Larsson A, Melhus H et al. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009;207:546–51. doi: 10.1016/j.atherosclerosis.2009.05.013.
21. Laukkanen JA, Khan H, Kurl S et al. Left ventricular mass and the risk of sudden cardiac death: a population-based study. J Am Heart Assoc. 2014;3:e001285. doi: 10.1161/JAHA.114.001285.
22. Inaba M, Okuno S, Imanishi Y et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int. 2006;17:1506–13. doi: 10.1007/s00198-006-0154-6.
23. Srivaths PR, Goldstein SL, Silverstein DM et al. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol. 2011;26:945–51. doi: 10.1007/s00467-011-1822-0.
24. Park CW, Oh YS, Shin YS et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis. 1999;33:73–81. doi: 10.1016/S0272-6386(99)70260-X.
25. Thorp ML, Johnson ES, Yang X et al. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology. 2009;14:240–6. doi: 10.1111/j.1440-1797.2008.01065.x.
26. Martinez-Vea A, Marcas L, Bardají A et al. Role of oxidative stress in cardiovascular effects of anemia treatment with erythropoietin in predialysis patients with chronic kidney disease. Clin Nephrol. 2012;77:171–81. doi: 10.5414/CN107309.
27. Drüeke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84. doi: 10.1056/NEJMoa062276.
28. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98. doi: 10.1056/NEJMoa065485.
29. Schüttler D, Schönermarck U, Wenner F et al. Large potassium shifts during dialysis enhance cardiac repolarization instability. J Nephrol. 2021;34:1301–5. doi: 10.1007/s40620-020-00880-4.
30. Weiss JN, Qu Z, Shivkumar K. Electrophysiology of hypokalemia and hyperkalemia. Circ Arrhythm Electrophysiol. 2017;10:e004667. doi: 10.1161/CIRCEP.116.004667.
31. Farkas JD, Long B, Koyfman A, Menson K. BRASH syndrome: bradycardia, renal failure, AV blockade, shock, and hyperkalemia. J Emerg Med. 2020;59:216–23. doi: 10.1016/j.jemermed.2020.05.001.
32. Orlov S, Cherney DZI, Pop-Busui R et al. Cardiac autonomic neuropathy and early progressive renal decline in patients with nonmacroalbuminuric type 1 diabetes. Clin J Am Soc Nephrol. 2015;10:1136–44. doi: 10.2215/CJN.11441114.
33. Schlaich MP, Socratous F, Hennebry S et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20:933–9. doi: 10.1681/ASN.2008040402.
34. Esler M. The autonomic nervous system and cardiac arrhythmias. Clin Auton Res. 1992;2:133–5. doi: 10.1007/BF01819669.
35. Baber U, Howard VJ, Halperin JL et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Circ Arrhythm Electrophysiol. 2011;4:26–32. doi: 10.1161/CIRCEP.110.957100.
36. Yu L, Huang B, Wang Z et al. Impacts of renal sympathetic activation on atrial fibrillation: the potential role of the autonomic cross talk between kidney and heart. J Am Heart Assoc. 2017;6:e004716. doi: 10.1161/JAHA.116.004716.
37. Pokushalov E, Romanov A, Corbucci G et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60:1163–70. doi: 10.1016/j.jacc.2012.05.036.
38. Yao C, Veleva T, Scott L et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. Circulation. 2018;138:2227–42. doi: 10.1161/CIRCULATIONAHA.118.035202.
39. Xintarakou A, Tzeis S, Psarras S et al. Atrial fibrosis as a dominant factor for the development of atrial fibrillation: facts and gaps. Europace. 2020;22:342–51. doi: 10.1093/europace/euaa009.
40. Vilaysane A, Chun J, Seamone ME The NLRP3 inflammasome promotes renal inflammation and contributes to ERC. J Am Soc Nephrol JASN. 2010. pp. 211732–44.
41. Chin LH, Hsu YJ, Hsu SC et al. The regulation of NLRP3 inflammasome expression during the development of cardiac contractile dysfunction in chronic kidney disease. Oncotarget. 2017;8:113303–17. doi: 10.18632/oncotarget.22964.
42. Yeyati NL, Adrogué HJ. Inappropriately high plasma renin activity accompanies chronic loss of renal function. Am J Nephrol. 1996;16:471–7. doi: 10.1159/000169046.
43. Ruiz-Ortega M, Lorenzo O, Suzuki Y et al. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens. 2001;10:321–9. doi: 10.1097/00041552-200105000-00005. (PubMed) (CrossRef) (Google Scholar)
44. Xiao HD, Fuchs S, Campbell DJ et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol. 2004;165:1019–32. doi: 10.1016/S0002-9440(10)63363-9. (PMC free article) (PubMed) (CrossRef) (Google Scholar)
Chen Shih , J. (2025). Relación entre inteligencia emocional y rendimiento académico en estudiantes de nivel superior de Arequipa en la postpandemia . Ciencia Y Reflexión, 4(2), 648–667. https://doi.org/10.70747/cr.v4i2.299
Alcántara , R. L. (2025). Acompañamiento Pedagógico Estrategia Colaborativa. Ciencia Latina Revista Científica Multidisciplinar, 9(3), 7881-7886. https://doi.org/10.37811/cl_rcm.v9i3.18412
Agila Mocha, R. J., Vivanco Ureña, C. I., León Bravo, F. E., & Reyes Carrión , J. P. (2025). Software Educativos para el Proceso de Enseñanza Aprendizaje de Matemáticas en Bachillerato. Ciencia Y Reflexión, 4(2), 1341–1369. https://doi.org/10.70747/cr.v4i2.334
Chen Shih , J. (2025). Relación entre inteligencia emocional y rendimiento académico en estudiantes de nivel superior de Arequipa en la postpandemia . Ciencia Y Reflexión, 4(2), 648–667. https://doi.org/10.70747/cr.v4i2.299
Quelal Morejón , C. E., Rogel Calderón , A. S., Loaiza Dávila , L. E., & Maqueira Caraballo, G. D. L. C. (2025). Los juegos predeportivos: una alternativa para la inclusión de estudiantes con Trastorno del Espectro Autista (TEA) a la clase de Educación Física. Arandu UTIC, 12(2), 2169–2189. https://doi.org/10.69639/arandu.v12i2.1055
Guadalupe Beltrán , E. S., Palomeque Zambrano, J. Y., & Loor Avila, B. A. (2025). Desafíos de la Educación Superior en Contextos Híbridos: Análisis de las Prácticas Docentes en la Universidad Estatal de Milagro durante el Periodo Académico 2025. Revista Veritas De Difusão Científica, 6(2), 1259–1281. https://doi.org/10.61616/rvdc.v6i2.685
Lozano Flores, L. D. (2025). Gamificación en el aprendizaje de unidades de tiempo: el caso de Sims 4. Emergentes - Revista Científica, 5(2), 68–86. https://doi.org/10.60112/erc.v5.i1.373
Velásquez Torres, A. O., González Bautista, G., Neira Vera , M., & García Montañez , A. M. (2025). Formación Docente en la Resolución Pacífica de Conflictos: Diagnóstico de una Necesidad Curricular en Colombia. Estudios Y Perspectivas Revista Científica Y Académica , 5(2), 2936–2952. https://doi.org/10.61384/r.c.a.v5i2.1329
Duarte Gahona, Y. K. (2025). Aplicación de la Inteligencia Artificial en la Personalización del Aprendizaje para Estudiantes con Necesidades Educativas Especiales . Revista Científica De Salud Y Desarrollo Humano , 6(2), 33–53. https://doi.org/10.61368/r.s.d.h.v6i2.575
45. Cao W, Song S, Fang G et al. Cadherin-11 deficiency attenuates Ang-II-induced atrial fibrosis and susceptibility to atrial fibrillation. J Inflamm Res. 2021;14:2897–911. doi: 10.2147/JIR.S306073.
46. Ishizaka N, Nakao A, Ohishi N et al. Increased leukotriene A(4) hydrolase expression in the heart of angiotensin II-induced hypertensive rat. FEBS Lett. 1999;463:155–9. doi: 10.1016/S0014-5793(99)01607-5.
47. Pueyo ME, Gonzalez W, Nicoletti A et al. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol. 2000;20:645–51. doi: 10.1161/01.ATV.20.3.645.
48. Goette A, Staack T, Röcken C et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. 2000;35:1669–77. doi: 10.1016/S0735-1097(00)00611-2.
49. Li Y, Li W, Yang B et al. Effects of cilazapril on atrial electrical, structural and functional remodeling in atrial fibrillation dogs. J Electrocardiol. 2007;40:100–e1–6. doi: 10.1016/j.jelectrocard.2006.04.001.
50. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res. 2002;54:456–61. doi: 10.1016/S0008-6363(02)00243-2.
51. Boldt A, Scholl A, Garbade J et al. ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol. 2006;101:261–7. doi: 10.1007/s00395-005-0571-2.
52. Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832–9. doi: 10.1016/j.jacc.2004.11.070.
53. Tanaka T, Nomura Y, Hirama C et al. Cardiac arrest during hemodialysis: a survey of five Japanese hospitals. Acute Med Surg. 2020;7:e476. doi: 10.1002/ams2.476.
54. Karnik JA, Young BS, Lew NL et al. Cardiac arrest and sudden death in dialysis units. Kidney Int. 2001;60:350–7. doi: 10.1046/j.1523-1755.2001.00806.x.
55. Douvris A, Malhi G, Hiremath S et al. Interventions to prevent hemodynamic instability during renal replacement therapy in critically ill patients: a systematic review. Crit Care. 2018;22:41. doi: 10.1186/s13054-018-1965-5.
56. Park S, Lee S, Kim Y et al. Atrial fibrillation and kidney function: a bidirectional Mendelian randomization study. Eur Heart J. 2021;42:2816–23. doi: 10.1093/eurheartj/ehab291.
57. El Hage N, Jaar BG, Cheng A et al. Frequency of arrhythmia symptoms and acceptability of implantable cardiac monitors in hemodialysis patients. BMC Nephrol. 2017;1:309. doi: 10.1186/s12882-017-0740-1.
58. Dalrymple LS, Go AS. Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:1487–93. doi: 10.2215/CJN.01290308.
59. James MT. Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. Arch Intern Med. 2008;168:2333. doi: 10.1001/archinte.168.21.2333.
60. Allon M, Depner TA, Radeva M et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO study. J Am Soc Nephrol. 2003;14:1863–70. doi: 10.1097/01.ASN.0000074237.78764.D1.
61. Bloom H, Heeke B, Leon A et al. Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery. Pacing Clin Electrophysiol. 2006;29:142–5. doi: 10.1111/j.1540-8159.2006.00307.x.
62. Baman TS, Gupta SK, Valle JA, Yamada E. Risk factors for mortality in patients with cardiac device-related infection. Circ Arrhythm Electrophysiol. 2009;2:129–34. doi: 10.1161/CIRCEP.108.816868.
63. Moss AJ, Hall WJ, Cannom DS et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–40. doi: 10.1056/NEJM199612263352601.
64. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83. doi: 10.1056/Nejmoa013474.
65. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37. doi: 10.1056/NEJMoa043399.
66. Turakhia MP, Varosy PD, Lee K et al. Impact of renal function on survival in patients with implantable cardioverter-defibrillators. Pacing Clin Electrophysiol. 2000;30:377–84. doi: 10.1111/j.1540-8159.2007.00678.x.
67. Sakhuja R, Keebler M, Lai T-S et al. Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator. Am J Cardiol. 2009;103:735–41. doi: 10.1016/j.amjcard.2008.11.014.
68. Korantzopoulos P, Liu T, Li L et al. Implantable cardioverter defibrillator therapy in chronic kidney disease: a meta-analysis. Europace. 2009;11:1469–75. doi: 10.1093/europace/eup282.
69. Makki N, Swaminathan PD, Hanmer J, Olshansky B. Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies. Europace. 2014;16:55–62. doi: 10.1093/europace/eut277.
70. Jukema JW, Timal RJ, Rotmans JI et al. Prophylactic use of implantable cardioverter-defibrillators in the prevention of sudden cardiac death in dialysis patients. Circulation. 2019;139:2628–38. doi: 10.1161/CIRCULATIONAHA.119.039818.
71. Okawa K, Miyoshi T, Sogo M et al. Improvement in renal and endothelial function after catheter ablation in patients with persistent atrial fibrillation. J Cardiol. 2020;76:610–7. doi: 10.1016/j.jjcc.2020.07.002.
72. Takahashi Y, Takahashi A, Kuwahara T et al. Renal function after catheter ablation of atrial fibrillation. Circulation. 2011;124:2380–7. doi: 10.1161/CIRCULATIONAHA.111.047266.
73. Naruse Y, Tada H, Sekiguchi Y et al. Concomitant chronic kidney disease increases the recurrence of atrial fibrillation after catheter ablation of atrial fibrillation: a mid-term follow-up. Heart Rhythm. 2011;8:335–41. doi: 10.1016/j.hrthm.2010.10.047.
74. Lee W, Wu P, Fang C et al. Impact of chronic kidney disease on atrial fibrillation recurrence following radiofrequency and cryoballoon ablation: a meta-analysis. Int J Clin Pract. 2021;75:e14173. doi: 10.1111/ijcp.14173.
75. Haïssaguerre M, Jaïs P, Shah DC et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659–66. doi: 10.1056/NEJM199809033391003.
76. Gallagher MM, Yi G, Gonna H et al. Multi-catheter cryotherapy compared with radiofrequency ablation in long-standing persistent atrial fibrillation: a randomized clinical trial. Europace. 2021;23:370–9. doi: 10.1093/europace/euaa289.
77. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406–12. doi: 10.1056/NEJM198908103210629.
78. Valembois L, Audureau E, Takeda A et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019;9:CD005049. doi: 10.1002/14651858.CD005049.pub5.
79. Waldo AL, Camm AJ, deRuyter H et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996;348:7–12. doi: 10.1016/S0140-6736(96)02149-6.
80. Tompkins C, Mclean R, Cheng A et al. End-stage renal disease predicts complications in pacemaker and ICD implants. J Cardiovasc Electrophysiol. 2011;22:1099–104. doi: 10.1111/j.1540-8167.2011.02066.x.
81. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. doi: 10.1056/NEJMoa0905561.
82. Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. doi: 10.1056/NEJMoa1107039.
83. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104. doi: 10.1056/NEJMoa1310907.
84. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. doi: 10.1056/NEJMoa1009638.
85. Medicines and Healthcare products Regulatory Agency. Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents. Drug Safety Update. 2020;13:5–7. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/896274/June-2020-DSU-PDF.pdf
86. Parker K, Thachil J. The use of direct oral anticoagulants in chronic kidney disease. Br J Haematol. 2018;183:170–84. doi: 10.1111/bjh.15564.
87. Elis A, Klempfner R, Gurevitz C et al. Apixaban in patients with atrial fibrillation and severe renal dysfunction: findings from a national registry. Isr Med Assoc J. 2021;23:353–8.
88. De Vriese AS, Caluwé R, Van Der Meersch H et al. Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol. 2021;32:1474–83. doi: 10.1681/ASN.2020111566.
89. Kimachi M, Furukawa TA, Kimachi K et al. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev. 2017;11:CD011373. doi: 10.1002/14651858.CD011373.pub2.
90. Genovesi S, Porcu L, Slaviero G et al. Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis. J Nephrol. 2021;34:63–73. doi: 10.1007/s40620-020-00774-5.
91. Mansour M, Karst E, Heist EK et al. The impact of first procedure success rate on the economics of atrial fibrillation ablation. JACC Clin Electrophysiol. 2017;3:129–38. doi: 10.1016/j.jacep.2016.06.002.
92. Brüggenjürgen B, Kohler S, Ezzat N et al. Cost effectiveness of antiarrhythmic medications in patients suffering from atrial fibrillation. Pharmacoeconomics. 2013;31:195–213. doi: 10.1007/s40273-013-0028-7. (PubMed) (CrossRef) (Google Scholar)
93. Neovius M, Jacobson SH, Eriksson JK et al. Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study. BMJ Open. 2014;4:e004251. doi: 10.1136/bmjopen-2013-004251.
94. Akhtar Z, Leung LWM, Sohal M, Gallagher MM. Leadless cardiac resynchronization therapy: a distant Utopia. Europace. 2021;23:81. doi: 10.1093/euro
Publicado
2025-08-12
Cómo citar
Cabrera Díaz , D. C., Duarte Morales , Y., Gil Sierra , D. J., Vivas Prada , M. A., Pardo Briñez , J. S., Cruz Acosta , M. F., Peña Gualteros , L., Manosalva Caro, A., & Rojas Velásquez , C. E. (2025). Arritmias en Enfermedad Renal Cronica, Mecanismos Implicados, Repercusion y Terapeutica de esta Compleja Asociacion. Ciencia Latina Revista Científica Multidisciplinar, 9(3), 10608-10636. https://doi.org/10.37811/cl_rcm.v9i3.18785
Número
Sección
Ciencias de la Salud
Derechos de autor 2025 Danna Carolina Cabrera Díaz , Yirena Duarte Morales , Daniel Jesús Gil Sierra , María Alejandra Vivas Prada , Jhonatan Smith Pardo Briñez , Manuel Fernando Cruz Acosta , Lynda Peña Gualteros , Adrian Manosalva Caro, Camilo Eliecer Rojas Velásquez
Esta obra está bajo licencia internacional Creative Commons Reconocimiento 4.0.
.png)
.png)
1.png)
